Back to Search Start Over

333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer

333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer

Details

ISSN :
09237534
Volume :
32
Database :
OpenAIRE
Journal :
Annals of Oncology
Accession number :
edsair.doi...........2dc19defaaeca4a92638bfecf62dc907
Full Text :
https://doi.org/10.1016/j.annonc.2021.08.616